Europe is a leader in cancer research. But turning that science into treatments that reach patients is another matter. Every minute, five people in Europe are diagnosed with cancer, and the disease costs the European economy more than €200 billion a year. Five years after its launch, Europe’s Beating Cancer Plan has been scrutinized by the European Court of Auditors and the European Parliament. Both back its ambitions but find delivery falling short, with national cancer plans often lacking the resources to succeed and access to care varying widely among member countries. Meanwhile, Europe’s share of global commercial clinical trials has almost halved in a decade.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.
